Vivos Therapeutics Stock Gains 12% After It Receives Medicare Approval for VidaSleep Oral Appliance
Shares of Vivos Therapeutics, Inc. (VVOS) is currently gaining over 12% on Tuesday morning after the medical technology company received medicare approval for VidaSleep oral appliance.
VVOS is currently trading at $3.5654, up $0.4054 or 12.8291%, on a large volume of 19.2 million, above average volume of 147 thousand, on the Nasdaq. The stock opened at $4.2200 after closing Monday at $3.1600. The stock has traded between $1.9700 and $6.2800 in the past 52-week period.
Vivos Therapeutics announced that its VidaSleep oral appliance, featuring Vivos' patented and U.S. Food and Drug Administration (FDA) cleared Unilateral Bite Block technology, has been approved by the Centers for Medicare & Medicaid Services (CMS) Pricing, Data Analysis and Coding (PDAC) contractor for the treatment of mild to moderate OSA and snoring in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.